Dual Subcellular Compartment Delivery of Doxorubicin to Overcome Drug Resistant and Enhance Antitumor Activity

Overview

Journal Sci Rep

Specialty Science

Date 2015 Nov 5

PMID 26530454

Citations 16

Authors

Yan-Feng Song

Dao-Zhou Liu

Ying Cheng

Miao Liu

Wei-Liang Ye

Bang-Le Zhang

Xin-You Liu

Si-Yuan Zhou

Affiliations

Soon will be listed here.

Abstract

In order to overcome drug resistant and enhance antitumor activity of DOX, a new pH-sensitive micelle (DOX/DQA-DOX@DSPE-hyd-PEG-AA) was prepared to simultaneously deliver DOX to nucleus and mitochondria. Drug released from DOX/DQA-DOX@DSPE-hyd-PEG-AA showed a pH-dependent manner. DOX/DQA-DOX@DSPE-hyd-PEG-AA induced the depolarization of mitochondria and apoptosis in MDA-MB-231/ADR cells and A549 cells, which resulted in the high cytotoxicity of DOX/DQA-DOX@DSPE-hyd-PEG-AA against MDA-MB-231/ADR cells and A549 cells. Confocal microscopy confirmed that DOX/DQA-DOX@DSPE-hyd-PEG-AA simultaneously delivered DQA-DOX and DOX to the mitochondria and nucleus of tumor cell. After DOX/DQA-DOX@DSPE-hyd-PEG-AA was injected to the tumor-bearing nude mice by the tail vein, DOX was mainly found in tumor tissue. But DOX was widely distributed in the whole body after the administration of free DOX. Compared with free DOX, the same dose of DOX/DQA-DOX@DSPE-hyd-PEG-AA significantly inhibited the growth of DOX-resistant tumor in tumor-bearing mice without obvious systemic toxicity. Therefore, dual subcellular compartment delivery of DOX greatly enhanced the antitumor activity of DOX on DOX-resistant tumor. DOX/DQA-DOX@DSPE-hyd-PEG-AA has the potential in target therapy for DOX-resistant tumor.

Citing Articles

Fiber optic-based integrated system for multiscale pharmacokinetic monitoring.

Li Y, Yang Y, Li W, Chen C, Lin Q, Huang H Biomed Opt Express. 2024; 15(6):3770-3782.

PMID: 38867773 PMC: 11166437. DOI: 10.1364/BOE.523179.

Nanomaterials in Medicine: Understanding Cellular Uptake, Localization, and Retention for Enhanced Disease Diagnosis and Therapy.

Peng Y, Yang Z, Sun H, Li J, Lan X, Liu S Aging Dis. 2024; .

PMID: 38421835 PMC: 11745437. DOI: 10.14336/AD.2024.0206-1.

Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy.

Cheng X, Feng D, Lv J, Cui X, Wang Y, Wang Q Cancers (Basel). 2023; 15(3).

PMID: 36765624 PMC: 9913854. DOI: 10.3390/cancers15030666.

Intramitochondrial co-assembly between ATP and nucleopeptides induces cancer cell apoptosis.

Choi H, Park G, Shin E, Shin S, Jana B, Jin S Chem Sci. 2022; 13(21):6197-6204.

PMID: 35733910 PMC: 9159100. DOI: 10.1039/d1sc05738c.

Polymeric Nanoparticles for Mitochondria Targeting Mediated Robust Cancer Therapy.

Sun Y, Yang Q, Xia X, Li X, Ruan W, Zheng M Front Bioeng Biotechnol. 2021; 9:755727.

PMID: 34692665 PMC: 8526929. DOI: 10.3389/fbioe.2021.755727.

References

Ye W, Du J, Zhang B, Na R, Song Y, Mei Q . Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles. PLoS One. 2014; 9(5):e97358. PMC: 4020841. DOI: 10.1371/journal.pone.0097358. View

Toninello A . Editorial: Mitochondria and subcellular organelles as treatment targets against pathological conditions. Curr Pharm Des. 2013; 20(2):153-4. DOI: 10.2174/13816128113199990038. View

Liu J, Huang Y, Kumar A, Tan A, Jin S, Mozhi A . pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv. 2013; 32(4):693-710. DOI: 10.1016/j.biotechadv.2013.11.009. View

Hann S, Tang Q, Zheng F, Zhao S, Chen J, Wang Z . Repression of phosphoinositide-dependent protein kinase 1 expression by ciglitazone via Egr-1 represents a new approach for inhibition of lung cancer cell growth. Mol Cancer. 2014; 13:149. PMC: 4061523. DOI: 10.1186/1476-4598-13-149. View

Du J, Song Y, Ye W, Cheng Y, Cui H, Liu D . PEG-detachable lipid-polymer hybrid nanoparticle for delivery of chemotherapy drugs to cancer cells. Anticancer Drugs. 2014; 25(7):751-66. DOI: 10.1097/CAD.0000000000000092. View

Hashim Y, Spitzer D, Vangveravong S, Hornick M, Garg G, Hornick J . Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. Mol Oncol. 2014; 8(5):956-67. PMC: 4082741. DOI: 10.1016/j.molonc.2014.03.005. View

Zong T, Mei L, Gao H, Cai W, Zhu P, Shi K . Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. Mol Pharm. 2014; 11(7):2346-57. DOI: 10.1021/mp500057n. View

Li S, Wu W, Xiu K, Xu F, Li Z, Li J . Doxorubicin loaded pH-responsive micelles capable of rapid intracellular drug release for potential tumor therapy. J Biomed Nanotechnol. 2014; 10(8):1480-9. DOI: 10.1166/jbn.2014.1846. View

Han M, Vakili M, Soleymani Abyaneh H, Molavi O, Lai R, Lavasanifar A . Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells. Mol Pharm. 2014; 11(8):2640-9. DOI: 10.1021/mp500038g. View

10.

Qiu L, Qiao M, Chen Q, Tian C, Long M, Wang M . Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin. Biomaterials. 2014; 35(37):9877-9887. DOI: 10.1016/j.biomaterials.2014.08.008. View

11.

Han J, Lee T, Tung C, Lee D . Design and synthesis of a mitochondria-targeting carrier for small molecule drugs. Org Biomol Chem. 2014; 12(48):9793-6. DOI: 10.1039/c4ob01981d. View

12.

Han H, Choi K, Ko H, Jeon J, Saravanakumar G, Suh Y . Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy. J Control Release. 2015; 200:158-66. DOI: 10.1016/j.jconrel.2014.12.032. View

13.

Wu H, Yao L, Mei J, Li F . Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy. Int J Clin Exp Pathol. 2015; 8(1):207-16. PMC: 4348858. View

14.

Mallick A, More P, Ghosh S, Chippalkatti R, Chopade B, Lahiri M . Dual drug conjugated nanoparticle for simultaneous targeting of mitochondria and nucleus in cancer cells. ACS Appl Mater Interfaces. 2015; 7(14):7584-98. DOI: 10.1021/am5090226. View

15.

Lu L, Zou Y, Yang W, Meng F, Deng C, Cheng R . Anisamide-Decorated pH-Sensitive Degradable Chimaeric Polymersomes Mediate Potent and Targeted Protein Delivery to Lung Cancer Cells. Biomacromolecules. 2015; 16(6):1726-35. DOI: 10.1021/acs.biomac.5b00193. View

16.

Mizusako H, Tagami T, Hattori K, Ozeki T . Active Drug Targeting of a Folate-Based Cyclodextrin-Doxorubicin Conjugate and the Cytotoxic Effect on Drug-Resistant Mammary Tumor Cells In Vitro. J Pharm Sci. 2015; 104(9):2934-40. DOI: 10.1002/jps.24428. View

17.

Wu H, Zhu L, Torchilin V . pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials. 2012; 34(4):1213-22. PMC: 3587181. DOI: 10.1016/j.biomaterials.2012.08.072. View

18.

Aprille J . Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev. 2001; 49(1-2):63-70. DOI: 10.1016/s0169-409x(01)00125-9. View

19.

Jung K, Reszka R . Mitochondria as subcellular targets for clinically useful anthracyclines. Adv Drug Deliv Rev. 2001; 49(1-2):87-105. DOI: 10.1016/s0169-409x(01)00128-4. View

20.

Weissig V, DSouza G, Torchilin V . DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria. J Control Release. 2001; 75(3):401-8. DOI: 10.1016/s0168-3659(01)00392-3. View